论文部分内容阅读
目的:观察哌甲酯治疗发作性睡病患儿血清胰岛素样生长因子结合蛋白-3(IGFBP-3)水平变化。方法:选择确诊的发作性睡病患儿30例为观察组,给予盐酸哌甲酯缓释片治疗4个月,采用化学发光法测定治疗前后IGFBP-3水平。另选择同期正常体检儿童30例为对照组。比较观察组治疗前后与对照组IGFBP-3水平的差异情况。结果:治疗前,观察组IGFBP-3水平显著高于对照组(P<0.05);经盐酸哌甲酯缓释片治疗4个月后,观察组IGFBP-3水平非常显著低于治疗前(P<0.01),且与对照组差异不显著(P>0.05)。结论:哌甲酯治疗发作性睡病可使患儿IGFBP-3恢复正常水平,可认为经有效治疗发作性睡病可能不影响患儿的身高及智能发育。
Objective: To observe the changes of serum insulin-like growth factor binding protein-3 (IGFBP-3) levels in children with narcolepsy treated with methylphenidate. Methods: Thirty children diagnosed as narcolepsy were selected as the observation group and given methylphenidate sustained-release tablets for 4 months. The levels of IGFBP-3 before and after treatment were determined by chemiluminescence. The other 30 cases of normal physical examination children were selected as the control group. The differences of IGFBP-3 levels between the observation group before and after treatment and the control group were compared. Results: Before treatment, IGFBP-3 level in the observation group was significantly higher than that in the control group (P <0.05). After treated with methylphenidate extended-release tablets for 4 months, the level of IGFBP-3 in the observation group was significantly lower than that before treatment <0.01), and there was no significant difference with the control group (P> 0.05). CONCLUSION: Methylphenidate treatment of narcolepsy can restore normal levels of IGFBP-3 in children. It is considered that the effective treatment of narcolepsy may not affect the height and intelligence development of children.